sever
hitherto
unknown
e
nucleosid
phosphonoamid
analog
anp
prepar
direct
nitrogen
reagent
crossmetathesi
waterund
ultrasound
irradi
two
diastereoisom
formal
identifi
xray
diffract
compound
evalu
larg
spectrum
dna
rna
virus
among
phosphonoamid
thymin
analogu
emerg
best
prodrug
varicellazost
viru
vzv
ec
valu
mm
wildtyp
thymidin
kinas
defici
strain
respect
select
index
mm
breakthrough
approach
pave
way
new
purin
pyrimidin
e
phosphonoamid
analog
abbrevi
vzv
varicella
zoster
viru
vv
vaccinia
viru
hsv
herp
simplex
viru
vsv
vesicular
stomat
viru
dna
deoxyribonucl
acid
rna
ribonucl
acid
compound
concentr
afford
inhibit
cell
growth
compound
concentr
afford
inhibit
viral
cytopath
mcc
minimum
cytotox
concentr
requir
afford
microscop
detect
alter
cell
morpholog
acn
acetonitril
dcm
dichloromethan
modifi
nucleosid
repres
major
class
therapeut
cancer
viral
diseas
among
acycl
nucleosid
phosphon
anp
pioneer
phosphonomethoxi
propyl
adenin
hpmpa
erik
de
clercq
form
key
class
drug
activ
variou
dna
virus
well
retrovirus
howev
compound
suffer
limit
reduc
cell
penetr
free
phosphon
acid
form
neg
charg
physiolog
ph
well
nephrotox
led
extens
search
new
anp
well
develop
prodrug
approach
enhanc
bioavail
cell
internalis
sever
anp
prodrug
market
adevofir
dipivoxyl
bispom
pmea
treatment
hepat
b
viru
hbv
tenefovir
disoproxyl
bispoc
pmpa
newli
tenofovir
alafenamid
treatment
human
immunodefici
viru
hiv
hbv
last
decad
group
develop
new
famili
anp
base
phosphon
scaffold
compound
directli
obtain
prodrug
highli
converg
modular
approach
base
power
olefin
acycl
cross
metathesi
cm
variou
allylphosphon
synthon
bear
biolabil
group
crotyl
allyl
pyrimidin
purin
approach
show
remark
breakthrough
synthesi
nucleosid
prodrug
compar
known
linear
approach
suffer
low
yield
also
clear
literatur
choic
prodrug
direct
impact
target
cell
releas
greatli
influenc
overal
outcom
effici
parent
drug
thu
follow
synthet
pathway
obtain
sever
prodrug
includ
commonli
use
carbonyloxymethyl
pronucleotid
pivaloyloxymethylor
pom
isopropyloxycarbonyloxymethylor
poc
also
alkoxyalkyl
monoest
hexadecyloxypropyl
hdp
octadecyloxyethyl
ode
sever
e
anp
prodrug
exhibit
remark
antivir
activ
dna
rna
virus
submicromolar
concentr
bi
pom
e
tbutp
prodrug
activ
sever
herpesvirus
ie
herp
simplex
viru
varicellazost
viru
vzv
repres
new
potenti
antivir
lead
despit
signific
amount
research
develop
aryl
phosphoramid
prodrug
report
mcguigan
develop
aryl
phosphonoamid
especi
field
anp
spare
investig
thu
articl
describ
inwat
ultrasound
promot
synthesi
antivir
evalu
hitherto
unknown
e
nucleosid
phosphonoamid
high
yield
fig
aryl
phosphonoamid
gener
obtain
treatment
parent
dimethylphosphon
nucleosid
tmsbr
correspond
silyl
ester
follow
subsequ
treatment
excess
phenol
lalanineoalkyl
ester
presenc
triphenylphosphin
aldrithiol
desir
product
often
isol
poor
yield
trace
state
prepar
phosphonoamid
prodrug
tenofovir
taf
order
avoid
low
yield
strategi
target
phenyl
phosphonoamid
e
anp
react
allyl
phenylphosphonoamid
nucleobas
acycl
cross
metathesi
cm
quit
challeng
take
account
poison
effect
nitrogen
cm
ruthenium
catalyst
attempt
obtain
desir
allyl
phosphonoamid
shortest
strategi
involv
introduct
allyl
group
phosphorodichlorid
give
desir
monoalkenyl
compound
fail
hand
despit
sever
condit
product
dialkyl
obtain
observ
scheme
therefor
decid
turn
attent
hphosphon
chemistri
dimethylphosphit
react
allyl
bromid
michaelisbeck
condit
give
dimethylallylphosphon
yield
import
quot
reaction
scaledup
g
substitut
ome
group
chlorin
presenc
oxalyl
chlorid
posit
substitut
phenol
gener
situ
give
mixtur
enantiom
yield
compound
treat
bromotrimethylsilan
dichloromethan
h
room
temperatur
give
phosphon
acid
monoest
deriv
excel
yield
scheme
follow
procedur
describ
gajda
et
al
phosphon
convert
variou
methyl
isopropyland
benzyllalanin
ester
order
compar
influenc
ester
group
phosphoru
chiral
activ
toxic
final
anp
compound
obtain
mixtur
diastereom
diastereom
compound
r
bn
separ
care
column
chromatographi
silica
gel
twice
compound
isol
singl
isom
respect
p
nmr
spectroscopi
confirm
isol
product
presenc
singl
peak
mixtur
isom
provid
two
peak
sit
drop
crystal
allow
obtain
crystal
molecul
structur
unambigu
determin
xray
p
r
p
respect
fig
next
silyl
thymin
obtain
min
room
temperatur
presenc
bistrimethylsilylacetamid
bsa
intermedi
directli
engag
nucleophil
substitut
reaction
crotyl
bromid
chlorotrimethylsilan
sodium
iodid
reaction
perform
ultrason
activ
afford
seven
hour
desir
compound
quantit
yield
convert
thymin
deriv
quantit
yield
scheme
partner
hand
turn
attent
olefin
cm
reaction
use
either
gener
grubb
catalyst
gii
reactiv
hoveydagrubb
hgii
catalyst
deriv
zhan
tabl
specif
cm
reaction
phosphonoamid
challeng
need
optim
sinc
state
previous
well
establish
literatur
compound
contain
basic
nitrogen
atom
poison
cm
ruthenium
catalyst
thu
problemat
substrat
olefin
metathesi
shown
presenc
electron
withdraw
group
next
nitrogen
decreas
electron
densiti
deactiv
catalyst
attenu
well
use
microwav
irradi
shown
also
presenc
lewi
acid
cu
salt
improv
yield
rcm
amino
acid
influenc
ultrason
also
test
optim
use
allylphosphonoamid
crotylthymin
taken
model
alkyl
thymin
react
dcm
diastereomer
mixtur
phosphonoamid
synthon
classic
heat
activ
entri
desir
compound
found
condit
test
equival
substrat
ru
catalyst
cocatalyst
lewi
acid
entri
thymin
deriv
use
microwav
irradi
mw
entri
sonic
entri
fail
also
use
water
sonic
led
expect
phosphonoamid
anp
moder
yield
entri
modul
condit
seal
tube
addit
surfact
polyoxyethanylatocopheryl
sebac
entri
improv
significantli
yield
reaction
thank
breakthrough
approach
e
thymidin
phosphonoamid
obtain
yield
rang
scheme
base
previou
data
analog
bioisoster
methyl
group
obtain
yield
respect
among
test
compound
bear
differ
biolabil
group
pom
poc
hdp
phosphonoamid
diastereomer
singl
phosphonoamid
form
potent
select
wildtyp
tk
thymidin
kinas
defici
tk
varicellazost
vzv
strain
ec
effect
concentr
valu
rang
mm
tabl
cytostat
activ
cc
decreas
factor
compar
compound
bi
pom
e
tbutp
result
select
index
si
ratio
cc
ec
superior
select
vzv
half
calcul
prodrug
show
also
activ
herp
simplex
viru
tk
herp
simplex
viru
strain
ec
rang
mm
compar
ec
obtain
cidofovir
tabl
diastereomer
singl
phosphonoamid
form
weak
activ
human
cytomegaloviru
hcmv
activ
higher
concentr
test
mm
vaccinia
viru
adenoviru
e
pyrimidin
phosphonoamid
inhibit
vzv
replic
ec
rang
mm
affect
cell
growth
morpholog
highest
test
concentr
mm
contrast
compound
antihsv
activ
abl
reduc
hcmv
scheme
reagent
condit
allyl
bromid
k
co
tbab
thf
c
b
cocl
dcm
c
et
n
phenol
dcm
c
c
tmsbr
dcm
rt
cocl
dmf
cat
dcm
rt
et
n
dcm
lalanin
benzyl
ester
hydrochlorid
rt
et
n
dcm
lalanin
methyl
ester
hydrochlorid
rt
et
n
dcm
lalanin
isopropyl
ester
hydrochlorid
rt
introduct
biolabil
prodrug
reveal
potenti
anp
inhibit
hcmv
replic
ec
rang
mm
compound
hitherto
undetect
pronucleotid
form
sever
hypothes
support
result
better
bioavail
molecul
phosphonoamid
form
compar
prodrug
form
activ
also
increas
better
halflif
less
toxic
sideproduct
howev
newli
synthes
prodrug
show
activ
vaccinia
viru
contrast
bi
pom
e
tbutp
phosphonamid
anp
activ
variou
viral
strain
chlorin
analog
shown
moder
activ
human
coronaviru
ec
mm
compound
also
evalu
differ
rna
virus
activ
found
describ
herein
synthesi
e
nucleosid
phosphonoamid
use
crossmetathesi
waterund
ultrasound
irradi
overal
yield
obtain
commerci
dimethylallylphosphon
well
data
report
literatur
prepar
phosphonoamid
two
diastereoisom
formal
identifi
xray
diffract
compound
evalu
variou
dna
virus
antivir
properti
among
thymin
analogu
show
best
prodrug
test
vzv
ec
mm
select
index
increas
compar
prodrug
breakthrough
approach
pave
way
new
purin
pyrimidin
e
phosphonoamid
gener
commerci
avail
chemic
reagent
grade
use
receiv
reaction
requir
anhydr
condit
carri
use
ovendri
glasswar
atmospher
dri
ar
reaction
microwav
irradi
perform
use
microwav
biotag
initi
mlseal
tube
reaction
ultrasound
carri
elmason
apparatu
frequenc
khz
effect
bold
charact
repres
tabl
best
yield
obtain
water
polyoxyethanylatocopheryl
sebac
pt
b
seal
tube
c
catalyst
introduc
mol
scheme
reagent
condit
thymin
gii
catalyst
mol
h
pt
c
gii
catalyst
mol
h
pt
c
gii
catalyst
mol
h
pt
c
power
w
reaction
monitor
thin
layer
chromatographi
tlc
analysi
use
silica
gel
plate
kieselgel
e
merck
column
chromatographi
perform
silica
gel
mm
e
merck
nmr
spectra
record
bruker
avanc
dpx
bruker
avanc
spectromet
use
deuter
solvent
intern
standard
chemic
shift
given
ppm
multipl
report
singlet
doublet
triplet
q
quartet
bs
broad
signal
multiplet
high
resolut
mass
spectra
perform
bruker
qtof
maxi
mass
spectromet
f
ed
erat
de
recherch
icoacbm
platform
lcm
data
acquir
thermofish
uhplcmsq
system
equip
electron
spray
ioniz
sourc
esi
temperatur
sourc
maintain
c
initi
cone
voltag
set
v
min
increas
full
scan
mode
data
acquir
mz
posit
mode
scan
time
addit
uv
detect
perform
diod
array
detector
three
wavelength
nm
respect
watermethanol
solut
mixtur
formic
acid
use
mobil
phase
composit
mobil
phase
increas
methanol
formic
acid
ramp
flow
rate
set
sampl
dilut
mobil
phase
inject
ml
column
xterra
water
mm
intern
diamet
mm
length
place
oven
c
convers
compound
equal
lcm
analysi
allylphosphonoamid
optim
term
separ
identif
reaction
crotylthymin
follow
lcm
electron
spray
ioniz
esi
posit
mode
three
compound
observ
allylphosphonoamid
h
homodim
form
h
phosphonoamid
anp
product
h
electron
extract
ion
perform
subsequ
area
correspond
chromatograph
peak
determin
convers
yield
determin
ratio
concentr
allylphosphonoamid
transform
initi
concentr
inert
atmospher
allyl
bromid
ml
mol
dissolv
thf
ml
mixtur
potassium
carbon
g
eq
tertbutylammonium
bromid
g
mol
mmol
final
dimethylphosphit
ml
eq
mol
ad
result
solut
stir
h
room
temperatur
follow
filtrat
solid
present
flask
filtrat
evapor
reduc
pressur
crude
product
distil
c
mm
hg
collect
differ
fraction
clean
product
obtain
colorless
liquid
g
mixtur
dimethylallylphosphon
g
eq
mmol
dcm
ml
oxalyl
chlorid
ml
eq
mmol
ad
reaction
stir
h
reflux
follow
remov
volatil
vacuo
obtain
methyl
allylphosphonochlorid
anoth
flask
solut
phenol
g
eq
mmol
triethylamin
ml
eq
mmol
dcm
stir
room
temperatur
phosphon
residu
dissolv
dcm
slowli
ad
solut
reflux
evapor
volatil
residu
purifi
silica
gel
column
chromatographi
elut
petroleum
etherethyl
acet
afford
colorless
oil
g
bromotrimethylsilan
ml
mmol
slowli
ad
solut
g
eq
mmol
dcm
ml
h
room
temperatur
evapor
volatil
crude
product
coevapor
time
methanol
ml
residu
purifi
flash
column
chromatographi
dcmmeoh
obtain
desir
product
amorph
white
solid
g
inert
atmospher
phenyloxi
allylphosphon
acid
eq
dissolv
dcm
catalyt
amount
dmf
eq
introduc
follow
addit
oxalyl
chlorid
eq
min
c
h
room
temperatur
volatil
remov
residu
dilut
ml
dcm
afford
solut
second
solut
prepar
lalanin
ester
chlorhydr
eq
freshli
distil
triethylamin
eq
dcm
mixtur
solut
slowli
ad
c
stir
h
room
temperatur
g
start
phosphon
solut
success
wash
ml
water
ml
naoh
ml
water
ml
hcl
ml
nahco
ml
water
workup
aqueou
phase
extract
ml
ethyl
acet
organ
phase
wash
brine
ml
dri
filter
evapor
residu
purifi
twice
flash
column
chromatographi
afford
desir
allylphosphonoamid
diastereomer
mixtur
diastereom
compound
separ
singl
diastereom
respect
titl
compound
obtain
follow
gener
procedur
start
compound
g
eq
mmol
residu
purifi
twice
flash
column
chromatographi
first
elut
peea
pentanediethyl
ether
diastereomer
mixtur
obtain
white
powder
g
diastereoisom
crystal
toluenepentan
mixtur
colorless
needl
respect
structur
establish
xray
titl
compound
obtain
follow
gener
procedur
start
compound
g
eq
mmol
obtain
residu
purifi
twice
flash
column
chromatographi
elut
peea
afford
nonsepar
mixtur
diastereoisom
colorless
oil
mg
titl
compound
obtain
follow
gener
procedur
start
compound
g
eq
mmol
obtain
residu
purifi
flash
column
chromatographi
elut
pe
ea
afford
nonsepar
mixtur
two
diastereoisom
colorless
oil
g
polyoxyethanylatocopheryl
sebac
pt
solut
water
phosphonoamid
eq
crotylnucleobas
eq
second
gener
grubb
catalyst
mol
ad
reaction
irradi
ultrasound
activ
c
khz
two
addit
portion
mol
grubb
catalyst
respect
ad
progress
reaction
follow
lcm
reaction
stop
h
ultrasoun
activ
maximum
phosphonoamid
convers
observ
volatil
remov
reduc
pressur
residu
submit
twice
flash
chromatographi
purif
firstli
dcmmeoh
follow
second
one
elut
tolueneaceton
titl
compound
obtain
follow
gener
procedur
start
singl
diastereom
phosphonoamid
mg
eq
mmol
crotylthymin
mg
mmol
eq
titl
compound
obtain
follow
gener
procedur
start
phosphonoamid
mg
eq
mmol
crotylthymin
mg
eq
mmol
obtain
residu
purifi
twice
flash
chromatographi
dcmmeoh
tolueneaceton
afford
white
solid
mg
titl
compound
obtain
follow
gener
procedur
start
phosphonoamid
mg
eq
mmol
crotylthymin
mg
eq
mmol
titl
compound
obtain
follow
gener
procedur
start
phosphonoamid
mg
eq
mmol
crotylthymin
mg
eq
mmol
titl
compound
obtain
follow
gener
procedur
start
phosphonoamid
mg
eq
mmol
mg
eq
mmol
obtain
residu
purifi
twice
flash
chromatographi
dcmmeoh
tolueneaceton
afford
white
solid
mg
titl
compound
obtain
follow
gener
procedur
start
phosphonoamid
mg
eq
mmol
mg
eq
mmol
obtain
residu
purifi
twice
flash
chromatographi
dcmmeoh
tolueneaceton
afford
compound
white
antivir
assay
antihiv
assay
base
inhibit
virusinduc
cytopath
plaqu
format
hel
herp
simplex
viru
ko
g
vaccinia
viru
vesicular
stomat
viru
human
cytomegaloviru
hcmv
varicellazost
viru
vzv
human
coronaviru
vero
sindbi
viru
coxsacki
hela
vesicular
stomat
viru
coxsacki
viru
respiratori
syncyti
viru
mdck
influenza
influenza
b
cell
cultur
confluent
cell
cultur
nearli
confluent
mdck
cell
microtit
plate
inocul
ccid
viru
ccid
viru
dose
infect
cell
cultur
plaqu
form
unit
pfu
vzv
presenc
vari
concentr
test
compound
viral
cytopath
effect
cpe
plaqu
format
vzv
record
soon
reach
complet
control
virusinfect
cell
cultur
treat
test
compound
antivir
activ
express
ec
compound
concentr
requir
reduc
virusinduc
cpe
viral
plaqu
vzv
plaqu
format
minim
cytotox
concentr
mcc
compound
defin
compound
concentr
caus
microscop
visibl
alter
cell
morpholog
altern
cytostat
activ
test
compound
measur
base
inhibit
cell
growth
hel
cell
seed
rate
cellswel
microtit
plate
allow
prolifer
h
medium
contain
differ
concentr
test
compound
ad
day
incub
c
cell
number
determin
coulter
counter
cytostat
concentr
calcul
cc
compound
concentr
requir
reduc
cell
prolifer
rel
number
cell
untreat
control
antivir
activ
compound
evalu
activ
primari
human
pbm
cell
cytotox
evalu
normal
pbm
cell
along
cem
vero
cell
